^
CANCER:

Ewing Sarcoma





Show legend
Group by Gene:
Include preclinical:

0
Multi-tyrosine kinase inhibitor
cabozantinib tablet
regorafenib
1
DNA synthesis inhibitor, Topoisomerase I inhibitor
temozolomide + irinotecan
2
Alkylating agent
melphalan + busulfan
3
Topoisomerase II inhibitor, RNA synthesis inhibitor
dactinomycin
4
LSD1 inhibitor
SP2577
5
PD1 inhibitor
pembrolizumab
IGF-1R inhibitor
6
IGF-1R inhibitor
CP-751,871
ASP7487
7
GD2 ganglioside inhibitor
dinutuximab beta
8
Alkylating agent, DNA inhibitor
trabectedin
9
Bcl2 inhibitor, Tubulin inhibitor
albumin-bound paclitaxel
VDC
OPEC
VC
10
Chemotherapy
GT
VIDE
VAIA
IE
11
CDK12 inhibitor
CDK12 inhibitor
12
mTOR inhibitor, IGF-1R inhibitor
mTOR inhibitor + IGF-1R inhibitor
13
Microtubule stabilizer, Tubulin polymerization promoter, DNA synthesis inhibitor
gemcitabine + docetaxel
14
Bifunctional alkylating agent, Topoisomerase II inhibitor, Alkylating agent, Topoisomerase I inhibitor
cyclophosphamide + ifosfamide + etoposide IV + topotecan
15
Tubulin polymerization inhibitor, DNA synthesis inhibitor, Topoisomerase I inhibitor
temozolomide + irinotecan + vincristine
16
Alkylating agent, Topoisomerase I inhibitor
cyclophosphamide + topotecan
17
Bifunctional alkylating agent, Topoisomerase II inhibitor, Tubulin polymerization promoter
carboplatin + ifosfamide + etoposide IV
18
RNA polymerase inhibitor, Alkylating agent, Apoptosis stimulant
lurbinectedin
19
EWS-FLI1 inhibitor, ETS inhibitor
ONCT-216
20
CDK4 inhibitor, CDK6 inhibitor
palbociclib
21
TRAIL R2 agonist
AMG 655
22
Bcl2 inhibitor
venetoclax
23
MEK inhibitor, Multi-tyrosine kinase inhibitor
trametinib + pazopanib
24
CDK4 inhibitor, CDK6 inhibitor, CDK9 inhibitor
DSP-2033
No biomarker
PTPRD R995C
PTPRD V253I + PTPRD W775stop
SPARC overexpression
TMB-H
MSI-H/dMMR
MGMT promoter methylation
IGF1R underexpression
IGF1 elevation
B4GALNT1 expression
EWSR1-FLI1 fusion
CD99 positive + VIM positive
IGF1R expression
MCL1 amplification
FUS-ERG fusion
CDKN2A deletion
PAK4 deletion
CASP8 overexpression
KDM1A overexpression
FGFR3 amplification + FGFR4 amplification + FLT4 amplification
BCL2 underexpression